Aspen And Bambusa File For IPOs, Extending 2026 Biotech Listing Push
The Catalyst Brief · Oct 10, 2026
Latest
Eli Lilly’s Expansion Strategy Mirrors Its Revenue Lead, As GLP-1 Cash Funds Broader R&D
The Catalyst Brief · Oct 10, 2026
BD Names Ferass Abuzaina To Lead Surgery Business, Signaling An Internal-Operator Bet
The Catalyst Brief · Oct 10, 2026
Nancy Krieger Warns Census Changes Could Weaken Public Health Data And Federal Resource Targeting
The Catalyst Brief · Oct 10, 2026
Across the beats
- AI in Drug Discovery
GSK Signs Chai Discovery After Wet-Lab Binders Across Tested Targets
The Catalyst Brief Oct 9, 2026 - Biopharmaceutical Industry
Viatris Buys Pacira For $1.65 Billion, Adding Exparel And Zilretta Ahead Of FAM Decision
The Catalyst Brief Oct 9, 2026 - Biotech Innovation
Endeavor Posts Phase 2b Taladegib Win In 213 IPF Patients, Setting Up FDA Phase 3 Talks
The Catalyst Brief Oct 9, 2026 - Healthcare Investment
TRexBio Raises $116.7 Million In IPO, Funding Treg Programs Into 2029
The Catalyst Brief Oct 9, 2026 - Medical Technology
Abbott Wins FDA Clearance For CardioMEMS App Upgrade, Adding At-Home Pressure Visibility
The Catalyst Brief Oct 6, 2026 - Regulatory & Policy
ARM Outlines Data-Reuse Playbook For Gene Editing, Aiming To Cut Rare-Disease Development Work
The Catalyst Brief Oct 10, 2026
Most read
BMO Backs Merck’s Post-Keytruda Setup, Flags Bristol Myers’ $30-Plus Billion 2028 Exposure
Oct 3, 2026
Sanofi Pays Regeneron $1 Billion Upfront For Four Early Immunology Assets, Extending A Fraught Dupixent Alliance
Oct 1, 2026
Pfizer Posts Phase 3 Litfulo Vitiligo Data, Setting Up FDA And EMA Filings
Oct 2, 2026
Xaira Reveals XA-1 And XA-4, Framing X-Design As A Drug-Ready Antibody Engine
Oct 3, 2026
More coverage
Regulatory & PolicyBetsy Pleasants Uses Reddit NLP To Track Abortion Access Barriers, Extending Real-Time Public Health Surveillance
Pleasants and colleagues analyzed thousands of posts from the Reddit forum r/abortion with natural language processing alongside qualitative review. Their findings reaffirmed familiar access barriers while surfacing additional issues including mail delays for abortion medications, low credibility of online ordering platforms, and fears about legal risk.
The Catalyst BriefOct 10, 2026
Trump Administration Investigates 9 Universities For Alleged J-1 Visa Fraud, Pressuring Biomedical Research Staffing
Vice President JD Vance said the Department of Labor is examining whether leading universities are using J-1 visas to bring in cheap labor rather than relying on domestic researchers. The announcement fits into a broader push to tighten rules and raise costs for international students and scholars, even as many of those measures face legal and practical challenges.
The Catalyst BriefOct 9, 2026
Biopharmaceutical IndustryNewron Details 4 Evenamide Deaths Across Trials, As FDA Hold Stays On ENIGMA-TRS 2
Newron’s update expands a safety issue that first surfaced with a patient death in April, when the FDA halted further U.S. enrollment in ENIGMA-TRS 2. The strategic question now is whether the company can satisfy the agency on a sodium-channel mechanism concern without slowing a broader Phase 3 effort that still spans an international study and ongoing recruitment outside the U.S.
The Catalyst BriefOct 9, 2026
Biopharmaceutical IndustryArgenx Stops Phase 3 UNITY In Sjogren’s, Cutting Off A $1.4 Billion Vyvgart Expansion Estimate
The setback narrows one of the most visible label-expansion paths for Vyvgart Hytrulo even as argenx keeps other immunology programs moving. It also highlights how difficult Sjogren’s disease remains in late-stage development, where placebo effects and endpoint sensitivity can derail assets that showed earlier promise.
The Catalyst BriefOct 9, 2026
Biopharmaceutical IndustryMerck Is Barred From Keytruda SC Sales In 8 European Countries, Delaying Its Patent-Extension Strategy
The Dutch ruling bars production, import, stocking or sale of Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. Together with an earlier German injunction, the decision disrupts Merck’s effort to move major European markets toward a subcutaneous version protected by different patents than intravenous Keytruda.
The Catalyst BriefOct 9, 2026
AI in Drug DiscoveryIambic Targets $135 Million IPO, Extending 2026 Biotech Listing Momentum
Iambic plans to offer 9.4 million shares at $15 to $17 each, a range that implies about $150 million in gross proceeds and approximately $135 million after expenses. The company said it would direct the money primarily to IAM1363, while also moving IAM217 and IAM-C1 forward and continuing to invest in its Enchant and NeuralPLexer models.
The Catalyst BriefOct 8, 2026
Regulatory & PolicyFDA Extends Mifepristone Safety Review Into 2027, Leaving U.S. Access Fight Unresolved
The filing is the first substantive public update on the reevaluation ordered by Health Secretary Robert F. Kennedy Jr. The agency said it is using a statistical data mining method to look for unknown safety concerns and is also considering petitions that seek changes to how the drug is prescribed and distributed.
The Catalyst BriefOct 8, 2026
Healthcare InvestmentOno Pays $80 Million Upfront For Biohaven IgG Degraders, Adding A Phase 3 Graves’ Asset In Asia
The agreement gives Ono access to Biohaven’s extracellular protein degrader platform at a point when BHV-1300 is already in phase 3 and two follow-on candidates remain behind it. For Biohaven, the transaction monetizes one of the R&D areas it chose to keep after cutting back broader ambitions in March.
The Catalyst BriefOct 8, 2026
Biopharmaceutical Industryargenx Advances FB102 After Phase 2 Celiac Endpoint Hit, Setting Up A Faster Run At IL-15 Pathway Competition
The trial in 126 adults linked FB102 to statistically significant improvement in villus height–to–crypt depth versus placebo at Day 78 during an oral gluten challenge. While argenx did not disclose detailed efficacy data beyond a 0.0176 p value for the primary analysis, it said the results support phase 3 development.
The Catalyst BriefOct 8, 2026
Biotech InnovationAtsena Reports Lighthouse Responses For ATSN-201, Setting Up A 2028 XLRS Filing Plan
The readout comes from the first two parts of the phase 1/2/3 Lighthouse study, where 18 patients were treated in one eye and three served as untreated controls. For a disease with no approved, disease-specific treatments, the result gives Atsena a clearer argument for carrying its lowest dose into the registrational stage.
The Catalyst BriefOct 8, 2026
Healthcare InvestmentTCGX Launches $600 Million Asia Fund, Extending Its Biotech Investing Model Into China And Beyond
TCGX Asia Life Sciences Fund I will operate separately from, but in close synergy with, the firm's Western investment vehicles. The expansion pairs fresh capital with an on-the-ground buildout led by former ArriVent Biopharma chief business officer Dandan Dong.
The Catalyst BriefOct 8, 2026
Regulatory & PolicyTrump Administration Proposes $70,000 OPT Fee, Raising Pressure On International STEM Training
The Department of Homeland Security said the fee would help combat alleged fraud and abuse in Optional Practical Training and help U.S. citizens compete against international applicants in the job market. Critics argue the proposal adds another layer of uncertainty to a system that many science trainees use as a bridge to longer-term work in the U.S.
The Catalyst BriefOct 8, 2026